scholarly journals Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

Haemophilia ◽  
2020 ◽  
Vol 26 (3) ◽  
pp. 494-502 ◽  
Author(s):  
Beatrice Nolan ◽  
Johnny Mahlangu ◽  
Ingrid Pabinger ◽  
Guy Young ◽  
Barbara A. Konkle ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Extension Study ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Fc Fusion Protein

scholarly journals Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A

Haemophilia ◽  
2017 ◽  
Vol 23 (3) ◽  
pp. 392-399 ◽  
Author(s):  
A. D. Shapiro ◽  
J. N. Mahlangu ◽  
D. Perry ◽  
J. Pasi ◽  
D. V. Quon ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Fc Fusion Protein ◽  
Bleeding Episodes

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

Haemophilia ◽  
2017 ◽  
Vol 24 (1) ◽  
pp. 77-84 ◽  
Author(s):  
J. Oldenburg ◽  
R. Kulkarni ◽  
A. Srivastava ◽  
J. N. Mahlangu ◽  
V. S. Blanchette ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Fc Fusion Protein ◽  
Joint Health

scholarly journals Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. 72-80 ◽  
Author(s):  
B. Nolan ◽  
J. Mahlangu ◽  
D. Perry ◽  
G. Young ◽  
R. Liesner ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Safety And Efficacy ◽  
Fc Fusion Protein

scholarly journals CLINICAL EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HAEMOPHILIA A PATIENT RECEIVING ON DEMAND TREATMENT ONLY

2021 ◽  
Vol 71 (1) ◽  
pp. 62-66
Author(s):  
Saima Zahir ◽  
Tahira Zafar ◽  
Altaf Hussain ◽  
Hamid Saeed Malik ◽  
Pervez Ahmed ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Armed Forces ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
On Demand ◽  
Group I ◽  
Fc Fusion Protein ◽  
Male Patients ◽  
Group Ii

Objective: To evaluate the efficacy of recombinant factor VIII FC fusion protein in haemophilia A patientreceiving on demand treatment only. Study Design: Comparative cross sectional study. Place and Duration of Study: Department of Hematology, Armed Forces Institute of Pathology and PakistanHemophilia Welfare Society, Rawalpindi, from Jun to Dec 2017. Methodology: Eighty-nine male patients of Hemophilia A already receiving recombinant factor VIII (20-30 Units/kg) on demand, with no history of inhibitors were included in study. Patients were divided as per age into paediatric and adult group and also on the basis of their basal factor VIII levels into severe, moderate and mild groups. Same patients were switched to recombinant factor VIII FC fusion protein (20-30 Units/kg) and its efficacy was measured and compared with recombinant Factor VIII in terms of dose requirement, injections, bleeds in six month period, presence of inhibitors and side effects. Results: Eighty nine male patients were studied. There was significant reduction in dose from median value of5750 units for group I to 4000 units for group II. Number of bleed in six month period were reduced from 5.3 ingroup I to 4.5 in group II. Number of injections were reduced on average to 1-2 injection per bleed in group II. No inhibitors were detected in group II. Conclusion: rFVIII Fc fusion protein has prolong activity and results in reduction of total dose, number of bleed,dose per bleed and has reduced antigenecity.

Sign in / Sign up

Export Citation Format

Share Document